EQ Stock Forecast: Equillium, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Equillium, Inc. is $7. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 52 of 100 as at 18 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Equillium, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (90): Sales and profits are climbing, and climbing faster than before.
Volatility (20): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
EQ stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on EQ, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Oct 2026 | Leerink Partners | Assumes | Outperform | $6.00 |
| 4 Sept 2026 | Roth Capital | Reiterates | Buy | $12 |
| 13 July 2026 | Piper Sandler | Initiates | Overweight | $20 |
| 2 June 2026 | Roth Capital | Reiterates | Buy | — |
| 28 May 2026 | Leerink Partners | Upgrade | Outperform | — |
| 28 May 2026 | Roth Capital | Reiterates | Buy | — |
| 17 Apr 2026 | Roth Capital | Reiterates | Buy | — |
| 16 Apr 2026 | B. Riley Securities | Initiates | Buy | — |
| 14 Apr 2026 | Raymond James | Initiates | Strong Buy | — |
| 13 Mar 2026 | Roth Capital | Initiates | Buy | — |
| 28 Mar 2025 | Leerink Partners | Downgrade | Market Perform | — |
| 1 Nov 2024 | Jones Trading | Downgrade | Hold | — |
| 19 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Apr 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 Dec 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Nov 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 Aug 2023 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 14 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for EQ.
This page is one stock. Monday covers all of them.
EQ appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
EQ vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 19 Nov 2026, Equillium, Inc. returned +10.9% against +9.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
EQ analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 2.3×
- EV / EBITDA
- —
Cheaper than 40% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −59.0%
- Return on assets
- −34.0%
- Dividend yield
- —
Higher than 20% of US stocks
Higher than 13% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Equillium, Inc. has a market value of $90.6M and an enterprise value of $27.1M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$18.0M.
Diluted earnings per share, trailing twelve months: −$0.20.
Free cash flow in the twelve months to 30 June 2026: −$20.1M.
Equillium, Inc. employs 14 people.
Data provided by Twelve Data
EQ and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at EQ’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Equillium, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about EQ
What is the EQ stock price forecast for 2026-2027?
The median 12-month analyst price target for Equillium, Inc. is $7, with estimates ranging from $4 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is EQ stock a buy right now?
Of the 9 analysts covering Equillium, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Equillium, Inc. 52 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank EQ?
As at 18 Nov 2026, Equillium, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (90 of 100).
Will EQ stock go up?
No one can know that. What the data says: the median 12-month target from 9 analysts is $7, and Ticker Nerd's factor model ranks Equillium, Inc. 52 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the EQ stock forecast for 2030?
No analyst covering Equillium, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EQ are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $20 over the next 12 months.
How has EQ stock performed over the past year?
Equillium, Inc. returned +10.9% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Equillium, Inc. do?
Equillium Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory disorders with high unmet medical need. Its current pipeline centers on immunology programs designed to modulate disease-driving immune pathways, including monoclonal antibody and cytokine-inhibitor approaches aimed at conditions such as graft-versus-host disease, lupus nephritis, ulcerative colitis, alopecia areata, and other immune-mediated diseases.
About Equillium, Inc.
Equillium Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory disorders with high unmet medical need. Its current pipeline centers on immunology programs designed to modulate disease-driving immune pathways, including monoclonal antibody and cytokine-inhibitor approaches aimed at conditions such as graft-versus-host disease, lupus nephritis, ulcerative colitis, alopecia areata, and other immune-mediated diseases. The company’s work spans immuno-inflammatory areas across transplant science, gastroenterology, rheumatology, dermatology, oncology, and related specialty care segments. Equillium Inc. operates as a research-driven biopharmaceutical business, advancing novel therapeutic candidates through clinical development and strategic collaborations to address complex diseases where existing treatment options remain limited. Headquartered in La Jolla, California, Equillium Inc. plays a focused role in the biotechnology market as a developer of targeted immune-modulating medicines.
CEO Mr. Bruce Steel · 14 employees · United States · https://www.equilliumbio.com